Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- CABYC
- Target Recruit Count
- 34
- Registration Number
- NCT00781781
- Locations
- 🇪🇸
Hospital Clinic i Provincial., Barcelona, Cataluña, Spain
🇪🇸Hospital Clinico de Valencia, Valencia, Comunidad Valenciana, Spain
🇪🇸Hospital Santa Creu i Sant Pau, Barcelona, Spain
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2012-01-02
- Lead Sponsor
- CABYC
- Target Recruit Count
- 30
- Registration Number
- NCT00505232
- Locations
- 🇪🇸
Clinica Moncloa, Madrid, Spain
🇪🇸Hospital Quiron, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- CABYC
- Registration Number
- NCT00504491
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸Althaia, Manresa, Barcelona, Spain
🇪🇸ICO Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
© Copyright 2024. All Rights Reserved by MedPath